A statistically based non-targeted pathological classification method for non-small cell lung cancer
Through micromass spectrometry imaging technology and statistical methods, non-targeted classification of non-small cell lung cancer is solved, and the problem of low accuracy of traditional pathological diagnosis is achieved, high accuracy classification of adenocarcinoma and squamous cell carcinoma is achieved, and individualization is provided. Basic information about treatment.
Patent Information
- Application Number
- CN202111147452.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-09-28
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2041-09-28
AI Technical Summary
Traditional pathological methods have low accuracy in the pathological diagnosis of non-small cell lung cancer, rely on the subjective experience of pathologists, and it is difficult to accurately distinguish adenocarcinoma from squamous cell carcinoma under poor tumor differentiation.
Using statistical micromass spectrometry imaging technology, non-targeted classification of small molecules in non-small cell lung cancer samples through principal component analysis (PCA), and using mass spectrometry imaging technology to obtain various small molecule compound components in cancer center tissues. Its changes are combined with software to carry out objective calculations and data statistics to achieve higher accuracy pathological classification.
It improves the accuracy and efficiency of pathotyping of non-small cell lung cancer, reduces the analytical workload, provides characteristics and markers of difference between adenocarcinoma and squamous cell carcinoma, and provides reliable molecular-level information for individualized treatment and research.
Smart Images

Figure CN114295706B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a medicine detection system, and in particular to a pathological typing method of non-targeted non-small cell lung cancer based on statistics. Background Art
[0002] Lung cancer is a heterogeneous disease. It is one of the malignant tumors with the fastest growing incidence and mortality rate and the greatest threat to people's health and life. According to reports, the incidence and mortality of lung cancer in many countries have increased significantly in the past 50 years. The incidence and mortality of lung cancer in men rank first among all malignant tumors, while the incidence and mortality of women rank second. The pathological types of lung cancer mainly include non-small cell lung cancer and small cell lung cancer. Non-small cell lung cancer accounts for about 80%-85% of lung cancer, including adenocarcinoma, squamous cell carcinoma, etc. Small cell lung cancer accounts for about 15%-20% of lung cancer.
[0003] The main basis for the selection of existing lung cancer treatment methods is pathological classification and staging diagnosis. Pathological classification is generally determined by histology: important classifications include small cell vs non-small cell, adenocarcinoma vs squamous cell carcinoma, etc. The distinction between various morphological subtypes of lung cancer is necessary in guiding patient management. Different pathological subtypes have different corresponding treatment strategies. For example, small cell undifferentiated lung cancer is highly malignant, easy to metastasize in the early stage, sensitive to radiotherapy and chemotherapy, and non-surgical treatment with systemic chemotherapy and local radiotherapy is its main treatment method. Non-small cell lung cancer mainly includes squamous cell carcinoma and adenocarcinoma. Surgery is the main choice for stage I and II non-small cell lung cancer, and some can be cured by combining postoperative adjuvant radiotherapy and chemotherapy. For non-small cell lung cancer, the tumor cells of adenocarcinoma grow faster, and most of them metastasize in the early stage, mainly in the blood, so they are more sensitive to chemotherapy drugs, and the reflex treatment effect is poor, so surgery, chemotherapy, immunotherapy, targeted therapy and other methods are often chosen. Squamous cell carcinoma develops relatively slowly. In the early stages, most invasions are local, with lymph node metastasis being the main route. Distant metastasis occurs relatively late, so squamous cell carcinoma is more sensitive to radiotherapy, and surgery, radiation, immunotherapy, and other methods are generally used.
[0004] In current clinical practice, histopathological examination is the gold standard for the diagnosis and classification of lung cancer. The traditional histopathological method is to obtain the lesion tissue through fixation, dewaxing, staining and other steps, make slices and observe its morphological characteristics under a microscope. The detection method has many steps, the waiting time is long, and the test results are somewhat subjective. Especially when the tumor is poorly differentiated and lacks the morphological characteristics of lung adenocarcinoma and lung squamous cell carcinoma, classification is more difficult. Therefore, the concept of non-small cell lung cancer with unclear histological type has emerged.
[0005] Lung cancer is a highly heterogeneous disease at the molecular level. Tumors with the same histological morphology have different molecular genetic changes, which leads to differences in lung cancer treatment response and prognosis. The emergence of more and more new chemotherapeutic and targeted drugs requires strict distinction between lung adenocarcinoma and lung squamous cell carcinoma. For example, the survival of lung adenocarcinoma patients significantly increases after the use of pemetrexed, and there is a risk of major bleeding when patients with lung squamous cell carcinoma use bevacizumab. The combination of albumin paclitaxel and cisplatin has a good effect in the treatment of advanced lung squamous cell carcinoma. Therefore, accurate classification is an inevitable requirement for individualized treatment of lung cancer.
[0006] In the prior art, in addition to histopathological examination for lung cancer typing, lung cancer typing is mainly carried out by biological protein, gene sequencing, etc. For example, in CN102084253A, the expression of at least two tumor marker genes of NCAM splice variants NCAM 120, NCAM140 and / or NCAM180, cytokeratin (CK), neuroendocrine specific protein (NSP)-reticulon (RTN1), synaptic vesicle protein (SYPH), chromogranin A (CHGA), thyroid transcription factor 1 (TITF-1), γ neuron-specific enolase (γNSE) and heat shock protein-47 (HSP47) is used to type and diagnose lung cancer. In CN109954148A, the autofluorescence intensity of the normal lung tissue of the subject is stimulated by excitation light between 440nm and 700nm to classify lung cancer. When the autofluorescence intensity of the normal lung tissue of the subject decreases by any value between 0% and 60%, the subject is diagnosed as having lung adenocarcinoma; when the autofluorescence intensity of the normal lung tissue of the subject decreases by any value between 70% and 100%, the subject is diagnosed as having lung squamous cell carcinoma.
[0007] Accurate pathological classification of lung cancer plays an extremely important role in the effective treatment of lung cancer and the study of the mechanism of lung cancer development. In recent years, it has become one of the research hotspots and focuses in related fields. Summary of the invention
[0008] This invention uses human non-small cell lung cancer clinical samples (adenocarcinoma and squamous cell carcinoma) as the research object, and introduces a non-targeted statistical typing study of non-small cell lung cancer (adenocarcinoma and squamous cell carcinoma) based on micro-mass spectrometry imaging technology.
[0009] The present invention aims to solve the shortcomings of low accuracy of pathological diagnosis of non-small cell lung cancer by observing tissue cell morphology through traditional pathological methods (including HE staining, immunofluorescence, etc.), and the need to rely on the personal experience level and subjective cognition of pathologists. By using mass spectrometry imaging technology, a large number of small molecule compound components with the same distribution properties as cancer center tissues and their change levels and trends are obtained. At the same time, small molecule substances are directly classified non-targeted by statistical means (principal component analysis, PCA), thereby achieving objective calculation and data statistics at the molecular level with the help of software, and effectively classifying non-small cell lung cancer with higher accuracy.
[0010] Directly performing non-targeted statistical PCA analysis on all fragments in the comprehensive mass spectrum helps reduce the workload of analysis and improves the intuitiveness and accuracy of statistical typing. Figure 3 As shown: In the Score Plot, by directly performing PCA analysis on 10 ROI regions (representing adenocarcinoma ROI regions and squamous cell carcinoma ROI regions respectively), two groups of statistical classifications directly corresponding to adenocarcinoma and squamous cell carcinoma can be obtained (the large circle on the right represents adenocarcinoma grouping, and the large circle on the left represents squamous cell carcinoma grouping). This method can directly obtain the results of different types of typing without complex marker analysis, which is simple, fast and accurate. In the Loading Plot, each point in the figure represents various small molecule fragments in the 10 ROI regions, and the more discrete the fragment points from the coordinate origin (such as the area shown by the large circle in the figure), the greater the contribution to the statistical classification results of the difference in typing. The corresponding characteristics and differential markers of adenocarcinoma and squamous cell carcinoma can be inferred through this non-targeted statistical result, accumulating the corresponding material information basis for the targeted analysis and research of markers of adenocarcinoma and squamous cell carcinoma.
[0011] The present invention provides a pathological classification system for non-small cell lung cancer, which comprises a frozen section system, a matrix sublimation system, an imaging mass spectrometry microscope system, and a data processing system; wherein a sample is sliced by the frozen section system; after the slice passes through the matrix sublimation system; an imaging mass spectrometry microscope system is used for analysis; the data processing system processes the mass spectrometry imaging data of the sample, selects at least 3 areas in a micrograph of a cancer center tissue imaging mass spectrometry microscope, performs principal component analysis (PCA) on ionized biomolecules, and classifies the non-small cell lung cancer accordingly.
[0012] Preferably, at least 4 regions are selected in the micrograph of the imaging mass spectrometry microscope, and preferably 5 or more regions are selected.
[0013] Preferably each area contains at least 100 collection points, preferably at least 150, 200, or 300 or more.
[0014] The pathological classification system of non-small cell lung cancer as described above is characterized in that non-small cell lung cancer is classified into adenocarcinoma and squamous cell carcinoma.
[0015] The pathological classification system for non-small cell lung cancer as described above is characterized in that the matrix sublimation system is an iMLayer Matrix Vapor Deposition System.
[0016] The pathological classification system for non-small cell lung cancer as described above is characterized in that the imaging mass spectrometry microscope is an imaging mass spectrometry microscope iMScope TRIO.
[0017] A pathological classification system for non-small cell lung cancer as described above is characterized in that the matrix coating conditions are:
[0018] Matrix type 9AA negative ion mode Substrate coating mode Sublimation method iMLayer Substrate sublimation thickness 9AA: 0.9μm .
[0019] A pathological classification system for non-small cell lung cancer as described above is characterized in that the imaging mass spectrometry analysis conditions are:
[0020]
[0021]
[0022] A pathological classification system for non-small cell lung cancer as described above is characterized in that the data processing system uses IMAGEREVEAL software to simultaneously process the mass spectrometry imaging data of adenocarcinoma and squamous cell carcinoma samples, and defines at least 3 areas in the mass spectrometry imaging micrographs of the cancer center tissue, each area containing at least 150 acquisition points, and then uses the Differential Analysis module in the IMAGEREVEAL software to perform PCA operations.
[0023] Preferably, at least 4, 5, 6, or 7 or more regions are defined in a micrograph of mass spectrometry imaging of cancer center tissue;
[0024] Preferably, each area contains at least 200, at least 250, at least 300, at least 350, at least 400, at least 500 collection points.
[0025] Preferably, the extent and location of the cancer center tissue can be determined by HE staining results of serial sections.
[0026] The pathological classification system of non-small cell lung cancer as described above is characterized in that the imaging mass spectrometry data analysis and processing conditions are:
[0027]
[0028] The present invention also provides the use of the above-mentioned pathological classification system for non-small cell lung cancer in the preparation of a pathological classification instrument for non-small cell lung cancer.
[0029] The present invention uses microscopic mass spectrometry imaging technology to conduct experimental research on adenocarcinoma and squamous cell carcinoma tissues of human non-small cell lung cancer. According to the experimental results, a variety of suspected markers with strong correlation with the pathological typing of adenocarcinoma and squamous cell carcinoma were found, and adenocarcinoma and squamous cell carcinoma were successfully statistically clinically typed in the case of non-targeted research. Imaging mass spectrometry technology provides accurate qualitative and quantitative information on the location of substances for pathological typing research at the molecular level for major diseases such as non-small cell lung cancer, and provides more reliable experimental data and basic information for multiple fields such as clinical pathology research and application. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 :Sample preparation and imaging of imaging mass spectrometry microscope;
[0031] Figure 2 :Schematic diagram of ROI area selection and processing of imaging data;
[0032] Figure 3 : Clinical statistical analysis of non-small cell lung cancer based on PCA. DETAILED DESCRIPTION
[0033] The present invention will be further described below with reference to the embodiments.
[0034] Example 1
[0035] 1. Sample preparation and loading: After clinical samples are frozen, they are sliced using a cryo-microtome. The prepared slices are subjected to matrix sublimation using the iMLayer Matrix Vapor Deposition System and then analyzed using the imaging mass spectrometer iMScope TRIO. Figure 1 Shown
[0036] Substrate coating conditions
[0037] Matrix type 9AA (negative ion mode) Substrate coating mode Sublimation method (iMLayer) Substrate sublimation thickness 9AA: 0.9μm
[0038] Imaging mass spectrometry analysis conditions
[0039] Analysis Mode Negative ion mode Collection range m / z 500-1000 Laser diameter 40μm Collection interval 40μm / 100μm
[0040] 2. Software processing and calculation: Use IMAGEREVEAL software to process the mass spectrometry imaging data of adenocarcinoma and squamous cell carcinoma samples at the same time. Determine the classification of adenocarcinoma and squamous cell carcinoma and the specific range and location of the cancer center tissue based on the HE staining results of continuous sections (circled areas). Circle 5 ROI areas (corresponding areas to the coils) in the micrographs of mass spectrometry imaging of adenocarcinoma and squamous cell carcinoma tissues, respectively. Each ROI area contains approximately 300 acquisition points. Then use the Differential Analysis module in IMAGEREVEAL software to perform PCA operations to compare the statistical differences and classifications between the two. The specific imaging mass spectrometry data analysis and processing conditions are processed as shown in the following table, as shown in 2.
[0041] Imaging mass spectrometry data analysis and processing conditions
[0042]
[0043] Directly performing non-targeted statistical PCA analysis on all fragments in the comprehensive mass spectrum helps reduce the workload of analysis and improves the intuitiveness and accuracy of statistical typing. Figure 3 As shown: In the Score Plot, by directly performing PCA analysis on 10 ROI regions (representing adenocarcinoma ROI regions and squamous cell carcinoma ROI regions respectively), two groups of statistical classifications directly corresponding to adenocarcinoma and squamous cell carcinoma can be obtained (the large circle on the right represents adenocarcinoma grouping, and the large circle on the left represents squamous cell carcinoma grouping). This method can directly obtain the results of different types of typing without complex marker analysis, which is simple, fast and accurate. In the Loading Plot, each point in the figure represents various small molecule fragments in the 10 ROI regions, and the more discrete the fragment points from the coordinate origin (such as the area shown by the large circle in the figure), the greater the contribution to the statistical classification results of the difference in typing. The corresponding characteristics and differential markers of adenocarcinoma and squamous cell carcinoma can be inferred through this non-targeted statistical result, accumulating the corresponding material information basis for the targeted analysis and research of markers of adenocarcinoma and squamous cell carcinoma.
[0044] The above description is a general description of the present invention. According to the situation or actual needs, changes in form and substitution of equivalents can be made. Although specific terms are used herein, these terms are intended to describe rather than limit the purpose. Those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A pathological classification system for non-small cell lung cancer, comprising a frozen section system, a matrix sublimation system, an imaging mass spectrometry microscope system, and a data processing system; wherein the sample is sliced by the frozen section system; after the slice passes through the matrix sublimation system; the imaging mass spectrometry microscope system is used for analysis; the data processing system processes the mass spectrometry imaging data of the sample, selects at least 3 areas in the micrograph of the imaging mass spectrometry microscope imaging of the cancer center tissue, performs principal component analysis (PCA) on the ionized biomolecules, and classifies the non-small cell lung cancer accordingly; the biomolecules are small molecules; The pathological classification is to classify non-small cell lung cancer into adenocarcinoma and squamous cell carcinoma; The matrix sublimation system is an iMLayer Matrix Vapor Deposition System; The imaging mass spectrometer is an imaging mass spectrometer iMScope TRIO; The coating conditions of the substrate are: The imaging mass spectrometry analysis conditions are: The data processing system uses IMAGEREVEAL software to simultaneously process the mass spectrometry imaging data of adenocarcinoma and squamous cell carcinoma samples, and defines at least three regions in the mass spectrometry imaging micrographs of the cancer center tissue, each region including at least 150 acquisition points, and then uses the Differential Analysis module in the IMAGEREVEAL software to perform PCA operations; The imaging mass spectrometry data analysis and processing conditions are:
2. Use of the pathological typing system for non-small cell lung cancer according to claim 1 in preparing a pathological typing instrument for non-small cell lung cancer.
